The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
phenox Inc.
Study ID
NCT07143019
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Flow diversion — DEVICE
    The p48 MW HPC and p64 MW HPC Flow Modulation Device is indicated for use in the treatment of intracranial aneurysms (IAs) arising from a parent vessel with a diameter of ≥2.0mm and ≤5.0 mm.

Study Details

To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.

Key Dates

Start date
Mar 16, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2032

Study Design

Enrollment
214 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention/Treatment
    Device: Flow diversion using the p48 MW HPC Device: Flow diversion using the p64 MW HPC

Primary Outcome Measure

Primary Efficacy and Performance Endpoint: Number of subjects with 100% occlusion of the target aneurysm without significant parent artery stenosis and no retreatment of the target aneurysm from the index procedure to the 12-month follow-up visit. [ Time Frame: 12 months ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
Barrow Neurological InstitutePhoenixArizona85013
Alex Reynolds
602-406-6227
Andrew Ducruet, MD (PRINCIPAL_INVESTIGATOR)
University of Colorado AnschutzAuroraColorado80045
Jennifer Maitlen, RN, BSN
303-724-1995
Joshua Seinfeld, MD (PRINCIPAL_INVESTIGATOR)
Swedish Medical Research CenterEnglewoodColorado80113
Ashley Thompson
303-907-5634
Don Frei, MD (PRINCIPAL_INVESTIGATOR)
Baptist Health Research InstituteJacksonvilleFlorida32207
Dollie Jennings, Ph.D
904-202-7063
Eric Sauvageau, MD (PRINCIPAL_INVESTIGATOR)
Piedmont Atlanta HospitalAtlantaGeorgia30309
Shardae Shavers
404-605-2277
Michael F Stiefel, MD, PhD (PRINCIPAL_INVESTIGATOR)
Advocate Lutheran General HospitalPark RidgeIllinois60068
Victor Arroyo, Arroyo
847-723-7950
Kathleen Hesse, BA, RN, CCRC
708-684-4690
Krishna Joshi, MD (PRINCIPAL_INVESTIGATOR)
University of IowaIowa CityIowa52242
Daniel F Waldschmidt
Kathleen Dlouhy, MD, MBA, MA (PRINCIPAL_INVESTIGATOR)
Tufts Medical CenterBostonMassachusetts02111
Ashley Paro
617-636-5000
Adel Malek, MD (PRINCIPAL_INVESTIGATOR)
UBNSBuffaloNew York14203
Michaela Laskowski
Adnan Siddiqui, MD, PhD, FAHA (PRINCIPAL_INVESTIGATOR)
North Shore University Hospital - Northwell HealthManhassetNew York11030
Betsy Moclair, RN, MBA,CCRC
917-673-4908
Athos Patsalides, MD (PRINCIPAL_INVESTIGATOR)
Stony Brook University HospitalStony BrookNew York11794
Marlene Baumeister, RN, BSN, CCRC, CNRN
631-444-1610
Dawn Madigan, RN, BSN,CCRC
David Fiorella, MD (PRINCIPAL_INVESTIGATOR)
East Carolina University Health Medical CenterGreenvilleNorth Carolina27834
Miriam Wood, MPH
252-744-5696
Richard T Dalyai, MD (PRINCIPAL_INVESTIGATOR)
The University of OklahomaOklahoma CityOklahoma73104
Sanaa Hameed
405-271-8001
Michael Omini
Hakeem Shakir, MD (PRINCIPAL_INVESTIGATOR)
Oregon Health & Science University Hospital (OHSU) / Oregon Stroke CenterPortlandOregon97239
Emma Blackburn
Ryan A Priest, MD (PRINCIPAL_INVESTIGATOR)
University of PennsylvaniaPhiladelphiaPennsylvania19104
Sophia Bautista
215-906-4165
Jan-Karl Burkhardt, MD (PRINCIPAL_INVESTIGATOR)
Vanderbilt University Medical CenterNashvilleTennessee37232
Morgan Mohler
615-421-1507
Rohan Chitale, MD (PRINCIPAL_INVESTIGATOR)
University of Washington - Harborview Medical CenterSeattleWashington98104
Tyler Ip
206-744-9389
Michael Levitt, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

By condition

Related Studies